NCT03140332View on ClinicalTrials.gov

Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib.

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

February 27, 2020

Study Completion Date

February 27, 2020

Conditions
Hepatocellular CarcinomaPerfusion Scanner
Interventions
OTHER

Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib

To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.

Trial Locations (1)

80054

CHU Amiens Picardie, Amiens

All Listed Sponsors
lead

Centre Hospitalier Universitaire, Amiens

OTHER

NCT03140332 - Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib. | Biotech Hunter | Biotech Hunter